These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2852695)

  • 1. Clinical use of the somatostatin analog SMS 201-995 in endocrinology.
    Cozzi R; Liuzzi A; Dallabonzana D; Oppizzi G; Orlandi P; De Palo C; Petroncini MM; Piolini M; Chiodini PG
    J Endocrinol Invest; 1988 Nov; 11(10):737-40. PubMed ID: 2852695
    [No Abstract]   [Full Text] [Related]  

  • 2. Octreotide: a somatostatin analog.
    Salman K; Rose LI
    Am Fam Physician; 1989 Jun; 39(6):207-11. PubMed ID: 2543196
    [No Abstract]   [Full Text] [Related]  

  • 3. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
    Gorden P; Comi RJ; Maton PN; Go VL
    Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin).
    Lamberts SW
    Acta Endocrinol Suppl (Copenh); 1986; 276():41-55. PubMed ID: 2875590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic use of somatostatin analogues in endocrinology].
    Faglia G; Arosio M
    Recenti Prog Med; 1992 Nov; 83(11):626-33. PubMed ID: 1363150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine applications of the somatostatin analogue octreotide (Sandostatin).
    Ezzat S; Melmed S
    Metabolism; 1992 Sep; 41(9 Suppl 2):34-8. PubMed ID: 1518431
    [No Abstract]   [Full Text] [Related]  

  • 7. [Malignant insulinoma: lack of response to the somatostatin analog SMS 201-955].
    Ligorria C; Montaña E; Virgili N
    Med Clin (Barc); 1989 Nov; 93(17):676. PubMed ID: 2559266
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
    Wynick D; Bloom SR
    J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.
    Rosenbaum A; Flourie B; Chagnon S; Blery M; Modigliani R
    Digestion; 1989; 42(2):116-20. PubMed ID: 2548911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical application of somatostatin-analogue].
    Tanaka K; Itoh S; Shimizu N
    Nihon Rinsho; 1990 May; 48(5):1084-8. PubMed ID: 2165538
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-acting somatostatin analog SMS 201-955 (Sandostatin) and its application in clinical gastroenterological practice].
    Meier R; Gyr K
    Schweiz Rundsch Med Prax; 1988 Aug; 77(31-32):813-9. PubMed ID: 2845555
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential indications for octreotide in endocrinology.
    von Werder K; Faglia G
    Metabolism; 1992 Sep; 41(9 Suppl 2):91-8. PubMed ID: 1518441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of insulinoma with the somatostatin analog SMS 201-995].
    Gilsanz Peral A; Gómez Balaguer M; Costa Talens P
    Med Clin (Barc); 1988 Apr; 90(15):634-5. PubMed ID: 2899658
    [No Abstract]   [Full Text] [Related]  

  • 14. Octreotide--a synthetic somatostatin.
    Med Lett Drugs Ther; 1989 Jul; 31(796):66-8. PubMed ID: 2567960
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G; Anderson JV; Williams SJ; Bloom SR
    Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
    Maton PN; Gardner JD; Jensen RT
    Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA; Bernstein R; Chynn KY; Kourides IA
    J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of somatostatinoma: responses to food and SMS 201-995 administration.
    Davis TM; Bray G; Domin J; Bloom SR
    Pancreas; 1988; 3(6):729-33. PubMed ID: 2906126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting somatostatin analogues in pancreatic islet cell carcinoma.
    Souquet JC
    Horm Res; 1989; 32(1-3):74-6. PubMed ID: 2559020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
    J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.